Pillar	Pillar 1	Pillar 2	Pillar 3	Pillar 4	Pillar 5
Area	Prevention and epidemic control	Diagnosis and treatment	Surveillance	Support and care	Advocacy and engagement
Aims	Achieving and sustaining high levels of coverage with licensed/WHO prequalified vaccines against the main causes of ABM in all countries. Introducing effective and affordable new vaccines against the causes of ABM including GBS*. Developing evidence-based strategies to give optimal individual and community protection against ABM. Developing context specific strategies to prevent GBS* infection in infants. Developing and improving strategies for epidemic prevention.	Improving diagnosis of meningitis at all levels of care. Developing and facilitating access to diagnostic assays at all levels of care. Identifying strategies for detecting mothers who are GBS* carriers. Providing and implementing appropriate, context-specific, quality-assured guidance and tools for treatment and supportive care.	Ensuring that effective systems for surveillance of meningitis and detection of its cause are in place in all countries. Developing guidance for detecting invasive GBS* diseases, especially in LIMIC. Developing and conducting surveys to establish the burden of post meningitis sequelae.	Strengthening early recognition and management of post meningitis sequelae in health care and community settings. Increasing the availability of, and access to, appropriate care and support for people affected by meningitis, their families and carers.	 Ensuring that funders and policy makers prioritize the roadmap and integrate it into country plans. Ensuring awareness of all populations of the symptoms, signs and consequences of meningitis so that they seek appropriate health care. Ensuring and raising awareness of communities about the impact of meningitis and available support for care after meningitis. Ensuring that people and communities know how to access meningitis vaccines and other preventive measure and support for care after meningitis, value and demand them. Maintaining high vaccine confidence.